Skip to content
The products offered on this site are intended for research purposes only. They are not intended for consumption or use by humans or animals.
Solkur .com
  • Shop
  • Vidensbase
  • Juridisk center
  • Contact
  • FAQ
  • Beregner
  • Kvalitet
  • Levering i EU
  • Om os
Languages
🇵🇱PL🇬🇧EN🇩🇪DE🇩🇰DA
Currencies
🇩🇰DKK🇵🇱PLN🇪🇺EUR🇨🇿CZK🇺🇸USD🇬🇧GBP🇸🇪SEK
🇵🇱PolskiPL🇬🇧EnglishEN🇩🇪DeutschDE🇩🇰DanskDA
🇩🇰Dansk kroneDKK🇵🇱Polski złotyPLN🇪🇺EuroEUR🇺🇸US dollarUSD🇬🇧British poundGBP🇸🇪Svensk kronaSEK🇨🇿Česká korunaCZK
Welcome to PUREPOINT Log in Create account
0
Home / Legal Center / Research Disclaimer

Legal document

Research Disclaimer

Operator
FIRSTSTONE TRADING sp. z o.o.
Version
2.0
Effective date
2026-06-06
Last updated
2026-08-09
Language
Polish
Legal contact
compliance@purepoint.pl

Store Operator: FIRSTSTONE TRADING spółka z ograniczoną odpowiedzialnością (FIRSTSTONE TRADING sp. z o.o.) Registered office: ul. Wierzbięcice 44A/40A, 61-568 Poznań, województwo wielkopolskie Voivodeship Correspondence address / Store service address: ul. Wierzbięcice 44A/40A, 61-568 Poznań KRS: 0001254766 (District Court Poznań – Nowe Miasto i Wilda in Poznań, 8th Commercial Division of the National Court Register, registration date: 17 February 2026) NIP: 7831958614 (100 shares of PLN 50 each, fully paid up) Representation: Krystian Dawidowski — Member of the Management Board (sole management board, individual representation) Electronic delivery address (ADE / e-Delivery): AE:PL-21312-60691-FGBFV-19 E-mail addresses: contact@purepoint.pl (Store) | compliance@purepoint.pl (legal / compliance) | k2benterprise.biz@gmail.com (registry / invoices) Store domain: purepoint.pl

Document version: 2.0 Effective date: 6 June 2026 Status: published — superior document (top of stack) Review cycle: quarterly

TABLE OF CONTENTS

  1. § 1. Purpose of the document and its primacy in the hierarchy of Store documents
  2. § 2. Definitions
  3. § 3. Legal nature of the Products — full negative regulatory classification
  4. § 4. Requirements for the Qualified Buyer — five categories and the Qualified Profile Declaration (KOP)
  5. § 5. Prohibition of use — list of absolutely prohibited conduct
  6. § 6. Sanctions for false declarations
  7. § 7. Limitation of the Operator’s liability
  8. § 8. Compliance with Polish law and the law of the European Union
  9. § 9. Exclusion of the consumer regime
  10. § 10. Product batch documentation — COA, LOT, MFG, EXP
  11. § 11. CLP-compliant labelling and REACH-compliant safety data sheets (SDS)
  12. § 12. Procedure for introducing amendments to this Research Disclaimer
  13. § 13. Clause on cooperation with public administration authorities and law enforcement authorities
  14. § 14. Bibliography — acts of Polish and EU law on which the document is based
  15. Change history
  16. Final clause

§ 1. Purpose of the document and its primacy in the hierarchy of Store documents

  1. This Research Disclaimer (hereinafter: the “Disclaimer”, the “Research Disclaimer” or the “document”) constitutes the superior document in relation to the remaining legal documents governing the operation of the online store conducted at the website address https://purepoint.pl (hereinafter: the “Store”) by the Operator, i.e. the company FIRSTSTONE TRADING spółka z ograniczoną odpowiedzialnością with its registered office in Poznań (KRS 0001254766), hereinafter referred to as the “Operator”.

  2. The purpose of this document is: 1) to provide an unambiguous, exhaustive and non-interpretable definition of the legal nature of the Products offered in the Store as exclusively research materials intended for in vitro laboratory work, which are not medicinal products, dietary supplements, cosmetics, medical devices, foodstuffs or biocidal products; 2) to define and limit the range of recipients of the Store exclusively to natural persons and legal persons satisfying the conditions of a Qualified Buyer (§ 4 of this Disclaimer); 3) to exclude the consumer law regime in relation to buyers conducting business, professional, research or academic activity (§ 9 of this Disclaimer); 4) to introduce an absolute prohibition on using the Products in any manner that would go beyond in vitro research work, including in particular the prohibition of consumption, administration to humans or animals, and medical, therapeutic, cosmetic and supplement use (§ 5 of this Disclaimer); 5) to make the Qualified Buyer aware of the scope of criminal and civil sanctions threatened for breach of the provisions of this document, in particular for making a false declaration of satisfying the conditions of a Qualified Buyer (§ 6 of this Disclaimer); 6) to limit the Operator’s liability within the bounds legally permissible in professional commercial dealings (§ 7 of this Disclaimer); 7) to describe the documentation procedures connected with each batch of the Product (Certificate of Analysis, batch number, manufacturing date, expiration date — § 10 of this Disclaimer); 8) to describe the rules for labelling the Products in accordance with Regulation (EC) No 1272/2008 (CLP) and the rules for making safety data sheets available in accordance with Regulation (EC) No 1907/2006 (REACH) — § 11 of this Disclaimer; 9) to set out the rules for the Operator’s cooperation with the public administration authorities of the Republic of Poland and law enforcement authorities (§ 13 of this Disclaimer).

  3. Primacy of the document in the hierarchy. In the event of any conflict between the provisions of this Research Disclaimer and the provisions of: 1) the Store Terms; 2) the Privacy Policy; 3) the Cookies Policy; 4) the Policy on Cookies and Other Tracking Technologies; 5) the Newsletter Terms; 6) the Complaints and Returns Policy; 7) any other legal, regulatory or informational document available within the Store — the provisions of this Research Disclaimer shall prevail.

  4. Acceptance clause. Each instance of creating an account in the Store, each instance of placing an order, and each instance of using the functionalities of the Store to an extent going beyond browsing the publicly available informational subpages is tantamount to: 1) having familiarised oneself with the content of this Research Disclaimer; 2) accepting its content in full wording; 3) making a declaration of satisfying the conditions of a Qualified Buyer, including a declaration within the Qualified Profile Declaration (KOP) defined in § 4 para. 6 of this Disclaimer.

  5. Exclusion of negotiability. The provisions of this Research Disclaimer are not subject to individual negotiation. The Operator does not consent to any change, modification, supplement or limitation of any of the provisions of this document on the basis of a separate arrangement with the Qualified Buyer, with the exception of amendments introduced under the procedure of § 12 of this document.

  6. Compliance status. This Research Disclaimer constitutes an element of the Operator’s compliance system and is a document on the content of which the Operator relies in the event of any control, explanatory, administrative, civil or criminal proceedings conducted in connection with the operation of the Store.

  7. Review and update cycle. The document is subject to periodic review on a quarterly basis, whereby an update may take place at any time under the procedure of § 12 of this Disclaimer in the event of a material change in the legal situation, in the event of a change in the practice of public administration authorities, in the event of a change in the Store’s product range, or in the event of a change in the Operator’s data.

§ 2. Definitions

  1. Whenever this Research Disclaimer refers to:

1) the “Operator” — this shall mean FIRSTSTONE TRADING spółka z ograniczoną odpowiedzialnością with its registered office in Poznań, ul. Wierzbięcice 44A/40A, 61-568 Poznań, województwo wielkopolskie Voivodeship, entered in the register of entrepreneurs of the National Court Register maintained by the District Court Poznań – Nowe Miasto i Wilda in Poznań, 8th Commercial Division of the National Court Register, under number KRS 0001254766, NIP 7831958614fully paid up, represented by a sole management board in the person of Mr Krystian Dawidowski holding the office of Member of the Management Board authorised to represent the Company individually;

2) the “Store” — this shall mean the online store conducted by the Operator at the website address https://purepoint.pl, comprising all subpages, functionalities and interfaces placed within the indicated domain;

3) the “Qualified Buyer” — this shall mean a natural person conducting business or professional activity, a legal person, or an organisational unit without legal personality to which specific provisions grant legal capacity, acquiring the Products for a purpose directly connected with the business, professional, research or academic activity it conducts within the meaning of Art. 43(1) of the Act of 23 April 1964 — the Polish Civil Code (consolidated text: Journal of Laws of 2025, item 250 [VERIFY — discrepancy with the Product Disclaimer, which indicates Journal of Laws of 2025, item 1610; harmonise the correct publication number], as amended, hereinafter: the “KC”), excluding a natural person performing a legal act with the Operator not directly connected with its business or professional activity (a consumer within the meaning of Art. 22(1) KC), whereby the Qualified Buyer must additionally satisfy the conditions of belonging to at least one of the five categories defined in § 4 para. 2 of this document;

4) the “Product” — this shall mean any material offered in the Store, in particular synthetic peptide compounds produced by methods of organic chemistry and solid phase peptide synthesis (SPPS), offered exclusively as research materials intended for in vitro laboratory studies, which are not a medicinal product, dietary supplement, cosmetic, medical device, foodstuff or biocidal product, for which the Operator publishes or makes available on request a Certificate of Analysis (COA) bearing the batch number (LOT), manufacturing date (MFG) and expiration date (EXP);

5) the “Research Material” — a concept identical to the Product; a term used interchangeably in a situation in which the context of the statement requires emphasis on the functional nature of the offered material as a chemical reagent intended exclusively for laboratory work;

6) the “KOP” or the “Qualified Profile Declaration” — this shall mean the set of declarations made by the Qualified Buyer in the course of creating an account in the Store, comprising five compliance declarations, the indication of the Qualified Buyer category, and supplementary data appropriate to the given category, in accordance with § 4 para. 6 of this document;

7) “in vitro” — this shall mean a laboratory study conducted on biological material located outside the living organism of a human or animal, under conditions of a controlled laboratory environment (e.g. in a test tube, on a culture plate, in a bioreactor), excluding any administration of a substance to the living organism of a human or animal (which would constitute an in vivo study, for which the Operator does not and cannot grant any authorisation with respect to the Products);

8) the “Pharmaceutical Law” or “PF” — this shall mean the Act of 6 September 2001 — Pharmaceutical Law (consolidated text: Journal of Laws of 2025, item 750; earlier consolidated text: Journal of Laws of 2024, item 686, as amended);

9) the “Civil Code” or “KC” — this shall mean the Act of 23 April 1964 — the Polish Civil Code (consolidated text: Journal of Laws of 2025, item 250 [VERIFY — discrepancy with the Product Disclaimer, which indicates Journal of Laws of 2025, item 1610; harmonise the correct publication number], as amended);

10) the “Penal Code” or “KK” — this shall mean the Act of 6 June 1997 — the Penal Code (consolidated text: Journal of Laws of 2025, item 17, as amended);

11) the “UPK” — this shall mean the Act of 30 May 2014 on Consumer Rights (consolidated text: Journal of Laws of 2024, item 1796, as amended);

12) the “GDPR (RODO)” — this shall mean Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (OJ EU L 119 of 4 May 2016, p. 1, as amended);

13) “CLP” — this shall mean Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ EU L 353 of 31 December 2008, p. 1, as amended);

14) “REACH” — this shall mean Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ EU L 396 of 30 December 2006, p. 1, as amended);

15) “COA” — this shall mean a Certificate of Analysis, i.e. a document issued by the manufacturer or an independent analytical laboratory, confirming the identity, chemical purity and analytical parameters of a given batch of the Product, in particular the results of analyses by high-performance liquid chromatography (HPLC) and mass spectrometry (MS);

16) “LOT” — this shall mean the production batch number of the Product enabling the unambiguous identification and association of a specific unit of the Product with specific COA analytical documentation;

17) “MFG” — this shall mean the manufacturing date of a given batch of the Product;

18) “EXP” — this shall mean the expiration date of a given batch of the Product, established on the basis of stability studies conducted by the manufacturer or an independent analytical laboratory;

19) “SDS” — this shall mean the Safety Data Sheet for a chemical substance, drawn up under Art. 31 of the REACH Regulation;

20) “control authorities” — this shall mean the public administration authorities and law enforcement authorities entitled to conduct controls or proceedings in matters connected with trade in medicinal products, dietary supplements, cosmetics, medical devices, foodstuffs, biocidal products, chemical substances, the protection of personal data, the protection of competition and consumers, and economic crime, in particular: a) the Chief Pharmaceutical Inspector (GIF) and voivodeship pharmaceutical inspectors, b) the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL), c) the Chief Sanitary Inspector (GIS) and the authorities of the State Sanitary Inspection, d) the President of the Personal Data Protection Office (UODO), e) the President of the Office of Competition and Consumer Protection (UOKiK), f) the authorities of the National Revenue Administration (including customs authorities), g) the Police and the prosecutor’s office (law enforcement authorities).

  1. The definitions introduced in this paragraph apply throughout the entire document. Where it is necessary to introduce additional definitions, they are placed directly in the content of the relevant paragraph.

§ 3. Legal nature of the Products — full negative regulatory classification

  1. The Operator declares expressly and unambiguously that the Products offered in the Store are exclusively research materials intended for in vitro laboratory work. The Operator firmly denies that the Products constitute any of the regulated categories described below.

For research purposes only. Not for human or animal consumption. For research purposes only. Not for human or animal consumption.

  1. The Products are NOT medicinal products within the meaning of Art. 2 point 32 of the Pharmaceutical Law and Art. 1 point 2 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ EU L 311 of 28 November 2001, p. 67, as amended).

Full wording of the cited provision (Art. 2 point 32 PF): “A medicinal product is a substance or mixture of substances presented as having properties of preventing or treating diseases occurring in humans or animals, or administered for the purpose of making a diagnosis or for the purpose of restoring, correcting or modifying the physiological functions of the organism through pharmacological, immunological or metabolic action.”

Functional justification of the exclusion: 1) The Operator does not present the Products as having properties of preventing or treating any disease in humans or animals. On the contrary — the Operator unambiguously prohibits such a manner of presentation and such a manner of use (§ 5 of this document). 2) The Operator does not declare, suggest or permit the suggestion that the Products are to be administered for the purpose of making a diagnosis or for the purpose of restoring, correcting or modifying the physiological functions of the organism of a human or animal. 3) The Products are offered exclusively in analytical packaging (typically glass vials with a capacity of 2–3 ml containing a lyophilisate of the active substance in a mass from 1 mg to 50 mg, with a hermetic aluminium or rubber closure dedicated to laboratory conditions), with an informational label bearing the clear inscription “FOR RESEARCH USE ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION”. 4) The Products are distributed exclusively to Qualified Buyers declaring use for in vitro laboratory work, excluding consumers (§ 4 and § 9 of this document). 5) The Operator does not hold — and does not apply for — a marketing authorisation for any medicinal product issued by the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, the European Medicines Agency (EMA), the European Commission, or any other competent national authority of a Member State of the European Union or a third country.

  1. The Products are NOT dietary supplements within the meaning of Art. 3 para. 3 point 39 of the Act of 25 August 2006 on Food and Nutrition Safety (consolidated text: Journal of Laws of 2023, item 1448, as amended) and Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ EU L 183 of 12 July 2002, p. 51, as amended).

Functional justification of the exclusion: 1) The Products are not foodstuffs and are not placed on the market as food. The Operator has not notified and does not intend to notify any of the Products to the public register of products covered by the notification of first placing on the market maintained by the Chief Sanitary Inspector. 2) The Products are not presented as concentrates of vitamins, minerals or other substances exhibiting a nutritional or other physiological effect for humans. 3) The Products are not placed on the market in a dosed form characteristic of dietary supplements (capsules, tablets, coated tablets, sachets of powder, ampoules, drops), but in the form of analytical laboratory vials containing a lyophilisate of the active substance, requiring reconstitution in a solvent solution (e.g. bacteriostatic water) exclusively for in vitro research purposes. 4) The Product label bears the unambiguous designation “FOR RESEARCH USE ONLY”, excluding use as food or a dietary supplement.

  1. The Products are NOT cosmetics within the meaning of Art. 2 para. 1 let. a of Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (OJ EU L 342 of 22 December 2009, p. 59, as amended) or within the meaning of the Act of 4 October 2018 on Cosmetic Products (Journal of Laws of 2018, item 2227, as amended).

Full wording of the cited provision (Art. 2 para. 1 let. a of Reg. 1223/2009): “A cosmetic product means any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours.”

Functional justification of the exclusion: 1) The Products are not intended for contact with the external parts of the human body. On the contrary — § 5 of this document expressly prohibits any contact of the Products with the skin, hair, nails, mouth, mucous membranes or any other part of the human body. 2) The Operator has not appointed and does not intend to appoint a person responsible for a cosmetic product within the meaning of Art. 4 of Regulation 1223/2009. 3) The Products do not hold and will not hold a cosmetic product safety assessment or a product information file (PIF) within the meaning of Art. 11 of Regulation 1223/2009. 4) The Products are not notified to the CPNP portal (Cosmetic Product Notification Portal) within the meaning of Art. 13 of Regulation 1223/2009 — and are not to be notified, because they are not cosmetics.

  1. The Products are NOT medical devices within the meaning of Art. 2 point 1 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ EU L 117 of 5 May 2017, p. 1, as amended) or within the meaning of the Act of 7 April 2022 on Medical Devices (Journal of Laws of 2022, item 974, as amended).

Functional justification of the exclusion: 1) The Products are chemical substances (peptide compounds) in the form of a lyophilisate, and not instruments, apparatuses, appliances, devices, software, implants, in vitro diagnostic reagents or any other device. 2) The Operator has not intended the Products for any of the purposes indicated in the definition of a medical device (diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of a disease, injury or disability in a human). 3) The Products do not bear and will not bear the CE marking under the medical device conformity assessment procedure. 4) The Operator is not a manufacturer, authorised representative, importer or distributor of a medical device within the meaning of Regulation 2017/745 and is not entered in any of the databases maintained under that Regulation (EUDAMED, national registers of medical devices).

  1. The Products are NOT foodstuffs within the meaning of Art. 2 of Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety (OJ EU L 31 of 1 February 2002, p. 1, as amended) or within the meaning of the Act of 25 August 2006 on Food and Nutrition Safety.

Functional justification of the exclusion: 1) The Products are not intended for human consumption or for administration to animals — on the contrary, § 5 of this document expressly prohibits any consumption, administration, oral, injectable, intranasal or conjunctival intake, and any other form of human or animal exposure. 2) The Operator is not a food business operator within the meaning of Art. 3 point 3 of Regulation (EC) No 178/2002. 3) The Products are not the subject of a notification to the District Sanitary Inspector or to any other authority of the State Sanitary Inspection under the procedures concerning food safety.

  1. The Products are NOT biocidal products within the meaning of Art. 3 para. 1 let. a of Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ EU L 167 of 27 June 2012, p. 1, as amended) or within the meaning of the Act of 9 October 2015 on Biocidal Products (consolidated text: Journal of Laws of 2024, item 211, as amended).

Functional justification of the exclusion: 1) The Products are not intended to destroy, deter, render harmless, prevent the action of, or otherwise exert a controlling effect on any harmful organism, by chemical or biological means. 2) The Operator has not applied for and does not apply for an authorisation to market a biocidal product or for entry in the Register of Biocidal Products maintained by the President of the URPL. 3) The Products are not presented as disinfectants, pest control products, preservatives or any other type of product covered by Annex V to Regulation 528/2012.

  1. Positive category — Products as research materials (research-use-only chemicals). The Products offered in the Store are exclusively: 1) chemical reagents in the form of synthetic peptides produced by methods of organic chemistry (typically Fmoc-SPPS — Solid Phase Peptide Synthesis with the fluorenylmethyloxycarbonyl protecting group), purified by chromatographic methods (reversed-phase HPLC with an acetonitrile/water gradient with the addition of TFA); 2) research materials intended exclusively for in vitro laboratory work conducted under conditions of a controlled laboratory environment; 3) analytical reagents distributed in analytical packaging with COA analytical documentation attached to each production batch (LOT); 4) chemical substances subject to the regime of the REACH Regulation (as substances for one’s own research and development purposes — Product and Process Oriented Research and Development, PPORD, or as substances registered in a quantity below 1 tonne per year exempt from the obligation of proper registration) and to the regime of the CLP Regulation (classification, labelling and packaging of chemical substances).

  2. No substitutive use. The Operator does not permit, suggest, indicate or inform that the Products may replace any medicinal product approved for use in humans or animals. The chemical or colloquial names under which the Products are offered (e.g. BPC-157, TB-500, GHK-Cu and others — whereby substances that are active substances of registered medicinal products are categorically excluded from the offer in accordance with the Product Disclaimer) are exclusively chemical names enabling the unambiguous identification of a chemical substance in scientific commerce and do not constitute a reference to any specific medicinal product authorised for marketing in any state. In particular, the Operator does not suggest pharmaceutical equivalence with any originator medicinal product or biosimilar.

§ 4. Requirements for the Qualified Buyer — five categories and the Qualified Profile Declaration (KOP)

  1. Exclusivity of access. The Store is conducted exclusively for Qualified Buyers. The Operator does not conduct sales to consumers within the meaning of Art. 22(1) KC. An attempt to make a purchase by a person not satisfying the conditions of a Qualified Buyer constitutes a breach of the terms of use of the Store and may result in the annulment of the order, the withholding of the release of the Product, the refund of the payment (after deduction of the actual costs of handling the order), and notification of law enforcement authorities in the event of detection of a false declaration (§ 6 of this document).

  2. Five categories of Qualified Buyer. The Operator distinguishes the following categories of Qualified Buyers:

1) STUDENT Category — a student of higher education studies of the first, second or third cycle (bachelor’s, master’s, uniform master’s, doctoral studies), studying in a biomedical, biochemical, chemical, biotechnological, pharmaceutical, veterinary or related field of study, in whose programme of study there are subjects in the area of organic chemistry, biochemistry, molecular biology or pharmacology. Required supplementary data: name of the university, field of study, year of study, student ID card number or e-mail address in the university domain.

2) LAB Category — a research, analytical, quality control or service laboratory, operating as an entrepreneur (a capital company, a partnership, a sole proprietorship) or as an organisational unit (e.g. a quality control laboratory department within a pharmaceutical, chemical, cosmetic, food or biotechnological enterprise). Required supplementary data: NIP number, full name of the laboratory / company name, address of the registered office / laboratory address, description of the activity conducted (scope of laboratory studies).

3) SCIENTIST Category — a research worker or a research and teaching worker employed at a higher education institution, a research institute of the Polish Academy of Sciences, a research institute (the Łukasiewicz network, a departmental institute), an international research organisation, or as an independent researcher with an active scientific output confirmed by publications in scientific journals. Required supplementary data: name of the home institution, position, ORCID identifier (Open Researcher and Contributor ID) or alternatively a Scopus Author ID / Web of Science Researcher ID, e-mail address in the institution’s domain.

4) BIZ_RD Category — an entrepreneur conducting business activity comprising research and development (R&D) work, the production of chemical products, the conduct of scientific research or development work, designated by a PKD code (Polish Classification of Activities): a) 74.10.Z — Activity in the field of specialised design, b) 72.11.Z — Scientific research and development work in the field of biotechnology, c) 72.19.Z — Scientific research and development work in the field of other natural and technical sciences, d) 72.20.Z — Scientific research and development work in the field of social sciences and humanities (to the extent that it comprises interdisciplinary research combining biomedical sciences with social sciences), e) 21.20.Z — Production of medicines and other pharmaceutical products (in respect of recipients conducting R&D work on new molecules, without the sale of Products as medicines or semi-finished products for medicines). Required supplementary data: NIP number, REGON number, full company name, address of the registered office, predominant PKD code and additional PKD codes comprising R&D activity, description of the research and development work conducted.

5) OTHER_PRO Category — another professional entity not falling within categories one to four, but satisfying the conditions of a Qualified Buyer (Art. 43(1) KC), in particular a physical preparation trainer conducting a sole proprietorship and using the Products for analytical work on biochemical processes at laboratory scale, a science journalist, an author of popular-science publications, an industry lobbyist, a patent attorney, a court expert, a court-appointed expert in the field of chemistry / biochemistry / toxicology. Required supplementary data: a substantive declaration in a text field of at least 100 characters in length describing the type of activity conducted and the nature of the use of the Products for in vitro laboratory work. The OTHER_PRO category is subject to manual review by the Operator — the account may be activated exclusively after a positive assessment of the declaration by an authorised compliance employee.

  1. Verification procedure. The Operator reserves the right to demand that the Qualified Buyer present documents confirming belonging to the declared category. In particular, the Operator may call upon the Qualified Buyer to provide in electronic form: 1) a certificate of student status — for the STUDENT category; 2) an extract from the KRS register of entrepreneurs or an entry in CEIDG — for the LAB and BIZ_RD categories; 3) a certificate of employment with scientific affiliation — for the SCIENTIST category; 4) confirmation of satisfying the conditions of the substantive declaration — for the OTHER_PRO category.

  2. Consequences of lack of verification. In the event of failure to present verification documents within 14 business days from the date of the demand, the Operator may: 1) suspend the Qualified Buyer’s account until the circumstances are clarified; 2) refuse to fulfil a specific order, refunding the payment reduced by handling costs (if the payment has already been made); 3) permanently delete the account from the Store’s database of Qualified Buyers (after exhausting the bilateral exchange of correspondence procedure).

  3. Age verification. A Qualified Buyer may only be an adult person (who has reached 18 years of age) possessing full capacity to perform legal acts. Minors, and persons partially or fully incapacitated, may not be Qualified Buyers and may not create an account in the Store or place orders.

  4. Qualified Profile Declaration (KOP). In the course of creating an account in the Store, the Qualified Buyer makes a Qualified Profile Declaration (KOP) comprising the following compliance declarations, ticked by the Qualified Buyer by means of separate checkboxes, without the possibility of any box being pre-ticked by the Operator:

1) First declaration (professional status): “I declare that I acquire the Products exclusively for a purpose connected with the business, professional, research or academic activity I conduct, and in particular for the purpose of conducting in vitro laboratory work under conditions of a controlled laboratory environment. I am not a consumer within the meaning of Art. 22(1) of the Act of 23 April 1964 — the Polish Civil Code.”;

2) Second declaration (prohibition of human and animal use): “I declare that I am aware that the Products offered in the Store are not medicinal products, dietary supplements, cosmetics, medical devices, foodstuffs or biocidal products, and I undertake never to consume the Products, never to administer them to humans or animals, and never to use them in any other manner bearing the hallmarks of therapeutic, medical, cosmetic or supplement use, or any other form of human or animal exposure.”;

3) Third declaration (prohibition of resale to a consumer): “I declare that I will not resell, transfer, lend or in any other manner make the Products available to consumers within the meaning of Art. 22(1) KC or to any third parties for the purpose of consumption, administration, therapeutic, supplement, cosmetic or biocidal use, or any form of use going beyond in vitro laboratory work.”;

4) Fourth declaration (awareness of sanctions): “I declare that I am aware that making a false declaration in this Qualified Profile Declaration may result in criminal liability under Art. 233 § 1 and § 6 of the Act of 6 June 1997 — the Penal Code (up to 8 years of imprisonment) and civil liability for damage suffered by the Operator under Art. 471 et seq. KC.”;

5) Fifth declaration (acceptance of documents): “I declare that I have familiarised myself with the content of the Research Disclaimer, the Store Terms, the Privacy Policy and the remaining legal documents of the Store, and I accept their content in full wording.”;

6) Indication of the Qualified Buyer category: The Qualified Buyer indicates one of the five categories (STUDENT / LAB / SCIENTIST / BIZ_RD / OTHER_PRO) and completes the supplementary data fields corresponding to the given category (§ 4 para. 2 of this paragraph).

  1. Electronic form of the declarations. The KOP is made in electronic form in the course of the account registration process in the Store. The Operator stores the content of the declarations together with the date and time of their making and the IP address from which the declarations were made, for the period necessary to achieve the purposes of the Store, to protect the Operator’s rights and to perform legal obligations, but no shorter than the limitation period for claims arising from the commercial relationship (10 years for pecuniary claims and correspondingly longer for claims arising from torts — Art. 118 and Art. 442(1) KC).

  2. Company account vs. individual account. The Operator permits the creation of accounts: 1) company accounts — in the case of the LAB and BIZ_RD categories, where the account represents an entrepreneur, and the natural person making the declarations acts as a representative / employee authorised to make purchases in the name and on behalf of that entrepreneur; 2) individual accounts — in the case of the STUDENT, SCIENTIST and OTHER_PRO categories, where the account represents a natural person conducting professional, research or academic activity.

  3. Prohibition of duplicating accounts. One natural person / one organisational unit may hold only one active account in the Store. The detection of duplicated accounts (e.g. with the same identifying data, from the same IP address within a close time interval, with attempts to circumvent the verification procedure) results in the suspension or deletion of the accounts.

§ 5. Prohibition of use — list of absolutely prohibited conduct

  1. The Operator introduces an absolute prohibition of the following conduct with respect to the Products acquired in the Store. Breach of any of the points of this paragraph results in the immediate cessation of the protection of the Qualified Buyer arising from the contract with the Store and may give rise to the criminal, civil and administrative liability of the Qualified Buyer (excluding the liability of the Operator within the scope specified in § 7 of this document).

  2. The following conduct is prohibited:

1) Consumption of the Products by humans in any form, including by swallowing, chewing, sucking, inhaling, sublingual intake, or oral intake in an aqueous solution or in another solvent;

2) Administration of the Products by the injectable route to humans in any manner, including subcutaneously, intramuscularly, intravenously, intra-arterially, intrathecally, intraperitoneally, intracerebroventricularly or by any other route of parenteral administration;

3) Administration of the Products intranasally, conjunctivally, aurally, vaginally, rectally or by any other route of administration through the mucous membranes of a human or animal;

4) Application of the Products to the skin or mucous membranes of a human for the purpose of obtaining any physiological, cosmetic, therapeutic or supplement effect (contact with the skin during laboratory work is treated as exposure to a chemical substance requiring the use of personal protective equipment in accordance with the safety data sheet SDS — § 11 of this document);

5) Administration of the Products to animals — both domestic animals (dogs, cats, domestic rodents), farm animals (cattle, swine, poultry, fur animals), and laboratory animals (the prohibition does not apply to authorised entities conducting experiments on animals on the basis of the Act of 15 January 2015 on the Protection of Animals Used for Scientific or Educational Purposes — Journal of Laws of 2023, item 465, as amended — and within an approved ethics committee protocol; in such a case the Qualified Buyer bears full liability for the compliance of the experiment with the regulations and scientific ethics, and the Operator bears no liability whatsoever for this);

6) Placing the Products on the market as medicinal products, dietary supplements, cosmetics, medical devices, foodstuffs or biocidal products — in particular by packaging them in packaging appropriate for those categories, providing them with labels suggesting such use, placing them for sale on platforms intended for consumers or in shops selling dietary supplements, pharmacies, herbal-medical shops, drugstores or grocery shops;

7) Advertising the Products as medicines, dietary supplements, cosmetics, weight-loss agents, anti-ageing, muscle regeneration, improvement of sports performance, treatment of diabetes, treatment of obesity, or any other therapeutic, preventive, cosmetic or nutritional properties in relation to humans or animals — in any medium, including on social media, internet forums, blogs, video channels, printed materials, influencer contacts;

8) Suggesting pharmaceutical interchangeability with originator medicines — in particular suggesting that a Product with the chemical name “semaglutide”, “tirzepatide”, “retatrutide”, etc., may replace the medicine Ozempic®, Wegovy®, Mounjaro®, Zepbound® or any other registered medicinal product, or that it constitutes a “cheaper alternative”, a “raw material for self-preparation of a medicine”, an “equivalent”, etc.;

9) Preparing from the Products self-made preparations for administration to humans or animals in any form (injectable suspension, capsules, drops, cream, ointment, balm, patch, inhalant), or conducting any instructions, tutorials, online courses, lectures or audiovisual materials instructing third parties on how to prepare such preparations independently;

10) Resale of the Products to third parties who are not Qualified Buyers, including to consumers within the meaning of Art. 22(1) KC, in any form of trade — resale in an online store, sale on an auction portal, sale on social forums, hand-to-hand sale, sale at fairs, in stationary shops, in pharmacies, parapharmaceutical points of sale, fitness clubs, gyms, beauty salons, beauty clinics, medical practices, veterinary practices;

11) Export of the Products to states subject to EU or international sanctions, in particular to the Russian Federation, the Republic of Belarus, the Islamic Republic of Iran, the Democratic People’s Republic of Korea, the Syrian Arab Republic, the Republic of Cuba, the Bolivarian Republic of Venezuela, the Republic of the Union of Myanmar, and to other jurisdictions subject at the relevant time to sanctions provided for in regulations of the Council of the European Union or decisions of the Security Council of the United Nations;

12) Using the Products for any purpose contrary to the universally binding law of the Republic of Poland or the law of the European Union, including for the manufacture of a psychoactive substance, narcotic drug, psychotropic substance, drug precursor, a doping agent covered by the list of prohibited substances of the World Anti-Doping Agency (WADA), a substance used in crimes against health, life or property, or for the commission of any other act prohibited under threat of penalty;

13) Mixing the Products with other substances in a manner that may pose a threat to the health or life of third parties, the natural environment or public order — in particular mixing with non-sterile solvents, preservatives unsuitable for analytical applications, or reactive substances that may form by-products with an unknown toxicity profile;

14) Placing on the market counterfeit Products appearing to originate from the Operator’s Store — in particular impersonating the Operator, copying labels, packaging, COA documentation, falsifying batch numbers (LOT) and using the “PUREPOINT” logo or other trademarks belonging to the Operator without the express consent of the Operator expressed in writing.

  1. Effects of breach of the prohibition. 1) Breach of any of the prohibitions listed in this paragraph results in the immediate blocking of the Qualified Buyer’s account and the withholding of the fulfilment of all orders not yet fulfilled. 2) The Operator retains the right to pursue compensation claims against the Qualified Buyer for damage suffered by the Operator as a result of the breach, in particular damage arising from administrative, control, criminal or civil proceedings instituted against the Operator in connection with the unlawful use of the Products by the Qualified Buyer. 3) In the event of a reasonable suspicion that the Qualified Buyer has used the Products to commit a crime, the Operator notifies the competent law enforcement authorities (the Police, the prosecutor’s office) in accordance with the procedure described in § 13 of this document.

§ 6. Sanctions for false declarations

  1. Criminal liability of the Qualified Buyer for a false declaration.

1) The making by the Qualified Buyer of a false declaration within the Qualified Profile Declaration (KOP) described in § 4 para. 6 of this Disclaimer may give rise to criminal liability under Art. 233 § 1 and § 6 of the Penal Code.

2) Full wording of the provision (Art. 233 § 1 and § 6 KK): “§ 1. Whoever, in giving testimony which is to serve as evidence in court proceedings or in other proceedings conducted on the basis of a statute, gives false testimony or conceals the truth, shall be subject to the penalty of imprisonment from 6 months to 8 years. § 6. The provisions of § 1–3 and 5 shall apply accordingly to a person who makes a false declaration, if a provision of a statute provides for the possibility of taking the declaration under pain of criminal liability.”

3) The Operator informs the Qualified Buyer that the KOP declarations are made under pain of criminal liability for making a false declaration. The clause informing of this pain is placed directly next to the KOP declarations in the course of the account registration process in the Store and takes the following form: “Aware of the criminal liability for making a false declaration (Art. 233 § 1 and § 6 of the Act of 6 June 1997 — the Penal Code: penalty of imprisonment from 6 months to 8 years), I declare as follows: [the KOP declarations follow here].”

4) Notification of law enforcement authorities. In the event of a reasonable suspicion that the Qualified Buyer has made a false KOP declaration, the Operator notifies the competent law enforcement authorities (the Police, the prosecutor’s office) of this fact under the procedure of Art. 304 § 1 of the Act of 6 June 1997 — the Code of Criminal Procedure (consolidated text: Journal of Laws of 2025, item 18, as amended).

  1. Civil liability of the Qualified Buyer for a false declaration.

1) Irrespective of the criminal liability indicated in paragraph 1 of this paragraph, the Qualified Buyer bears civil liability towards the Operator for damage suffered by the Operator as a result of making a false declaration, under the procedure of:

  a) **Art. 471 KC** — liability for non-performance or improper performance of an obligation; full wording of the provision:
  "A debtor shall be obliged to remedy the damage arising from the non-performance or improper performance of an obligation, unless the non-performance or improper performance is a consequence of circumstances for which the debtor bears no liability.";

  b) **Art. 472 KC** — failure to exercise due diligence;

  c) **Art. 415 KC** in conjunction with Art. 416 KC — liability for a tort, if making a false declaration constitutes an unlawful and culpable act and remains in an adequate causal connection with the Operator's damage.

2) Scope of damage covered by compensation. The Qualified Buyer is liable towards the Operator for the full amount of the damage, including for: a) damnum emergens — the actual financial loss suffered by the Operator (e.g. the costs of legal handling of proceedings conducted against the Operator in connection with the breach, the costs of administrative penalties imposed on the Operator, the costs of the loss of commercial contracts, the costs of withdrawing batches of the Products from the market, the costs of a post-incident compliance audit); b) lucrum cessans — the lost benefits that the Operator could have achieved had the breach not occurred, to the extent that the lost benefits are the result of a specific, proven breach; c) non-pecuniary damage (redress) — to the extent that the breach caused damage to the good name, reputation or image of the Operator and is recoverable under Art. 448 KC in conjunction with Art. 23 and Art. 24 KC.

3) The Qualified Buyer also bears civil liability towards the Operator in the event that the false declaration is not subsequently presented before a court or a public administration authority — the mere fact of misleading the Operator as to a material circumstance (the status of the Qualified Buyer) gives rise to liability under Art. 471 KC.

  1. Administrative liability. In the event of a breach of the provisions of pharmaceutical law, the law on cosmetic products, the law on dietary supplements, the law on medical devices, biocidal law, or other provisions governing trade in dangerous substances, administrative sanctions (financial penalties, decisions on withdrawal from the market, decisions on revocation of authorisation) may be imposed on the perpetrator of the breach. The Operator bears no administrative liability for the unlawful actions of the Qualified Buyer after the release of the Product from the Operator’s warehouse.

  2. Rebuttal of the presumption of good faith. In the event of making a false KOP declaration, the presumption of the Qualified Buyer’s good faith (Art. 7 KC) is rebutted in relation to the Operator’s claims arising from that breach.

  3. No exculpation arising from a mistake as to the law. The Qualified Buyer’s invocation of a lack of knowledge of the provisions of the law does not constitute a circumstance exempting from liability (ignorantia iuris nocet — Art. 5 and Art. 6 of the Act of 20 July 2000 on the Promulgation of Normative Acts and Certain Other Legal Acts — consolidated text: Journal of Laws of 2019, item 1461, as amended; and Art. 30 § 1 KK in fine as regards awareness of unlawfulness).

§ 7. Limitation of the Operator’s liability

  1. General limit of liability. The Operator bears liability towards the Qualified Buyer exclusively within the scope arising from the universally binding provisions of Polish law and from the provisions of the concluded contract of sale. All limitations and exclusions of liability specified in this paragraph apply to the full extent permitted by Polish law and the law of the European Union and apply in full in professional commercial dealings between entrepreneurs (B2B), in which the Qualified Buyer is an entity conducting business, professional, research or academic activity within the meaning of Art. 43(1) KC, and not a consumer within the meaning of Art. 22(1) KC.

  2. Liability cap (monetary limitation). The Operator’s total compensatory liability towards the Qualified Buyer in respect of a single order is limited to the value of that order increased by the shipping costs paid by the Qualified Buyer within that order. The above limitation applies irrespective of the legal basis of the claim (contractual, tortious, statutory) and irrespective of whether the damage arises from one event or from many events.

  3. Exclusion of lost benefits (lucrum cessans). The Operator bears no liability for the lost benefits (lucrum cessans) of the Qualified Buyer arising from the inability to use the Product, a delay in delivery, a change in the physicochemical properties of the Product during transport, an error in the COA documentation, a delay in updating the label, or any other circumstances indirectly connected with the performance of the contract of sale. In particular, the Operator bears no liability for: 1) the lost commercial contracts of the Qualified Buyer; 2) lost subsidies, grants, donations, public funds; 3) lost revenue from scientific publications whose deadline was not met as a result of a delay in the delivery of the Product; 4) lost benefits from contracts with third parties (clients, business partners of the Qualified Buyer); 5) lost benefits from patents, patent applications, inventions, whose protection was jeopardised as a result of a delay in the research work of the Qualified Buyer.

  4. Exclusion of indirect damage (consequential damages). The Operator bears no liability for any indirect damage arising from the contract of sale or from the unlawful use of the Product by the Qualified Buyer or a third party, including for damage suffered by: 1) the personnel of the Qualified Buyer’s laboratory; 2) third parties making use of the results of the research work of the Qualified Buyer; 3) persons to whom the Qualified Buyer made the Product available in breach of § 5 of this document; 4) public entities, including public administration authorities and law enforcement authorities, in the event of the institution of proceedings against the Qualified Buyer.

  5. Exclusion of liability for unlawful use of the Product. The Operator bears no liability whatsoever for any damage suffered by the Qualified Buyer or a third party as a result of: 1) consumption of the Product by a human; 2) administration of the Product to a human by any route of administration; 3) administration of the Product to an animal (excluding experiments conducted lawfully on the basis of the Act of 15 January 2015 on the Protection of Animals Used for Scientific or Educational Purposes — Journal of Laws of 2023, item 465, as amended, where liability for the correctness of the experiment is borne entirely by the Qualified Buyer conducting the experiment); 4) use of the Product for any purpose other than in vitro laboratory work; 5) preparation from the Product of any preparation for administration to humans or animals; 6) resale of the Product to third parties, including consumers.

In the above cases, full liability is borne by the perpetrator of the breach, i.e. the Qualified Buyer who committed the act, or the third party who came into possession of the Product in breach of the provisions of this Disclaimer.

  1. Exclusion of liability for compliance with the provisions of a third country. The Operator bears no liability for the compliance of the Products with the provisions of third countries (countries outside the European Economic Area) to which the Product is transported or in which it is used by the Qualified Buyer. The burden of ensuring compliance with the law of the destination country (in particular with customs law, pharmaceutical law, chemical law, the law on controlled substances) rests exclusively on the Qualified Buyer.

  2. Exclusion of liability for the actions of payment operators and courier companies. The Operator bears no liability for the actions or omissions of: 1) the payment operators servicing the Store (Stripe Payments Europe Limited); 2) the banks servicing BACS / SEPA bank transfers; 3) the courier and postal companies servicing the shipment of the Products (e.g. destruction of the parcel in transit, a delay in delivery caused by force majeure or improper handling by the courier); 4) the hosting operator cyber_Folks S.A.; 5) the analytics operator Plausible Insights OÜ with its registered office in Tallinn (Estonia); 6) the newsletter operator Sendinblue SAS with its registered office in Paris (France, the Brevo brand).

  3. Limits of the limitations. The limitations and exclusions of liability specified in this paragraph do not cover situations in which the Operator would cause damage to the Qualified Buyer through wilful fault (dolus) — to that extent the Operator’s liability remains full, in accordance with Art. 473 § 2 KC.

  4. Exclusion of the B2B warranty. In accordance with Art. 558 § 1 KC, in professional commercial dealings between entrepreneurs, the parties may extend, limit or exclude liability under the warranty for physical and legal defects of the Product. The Operator, in this Research Disclaimer and in the Store Terms, excludes the B2B warranty in full. The Qualified Buyer is obliged to examine the Product at the moment of receipt and to report immediately any visible defects or non-conformities with the description (in accordance with Art. 563 KC). Full wording of Art. 558 § 1 KC: “The parties may extend, limit or exclude liability under the warranty. If the buyer is a consumer, the limitation or exclusion of liability under the warranty is permissible only in the cases specified in specific provisions.” The exclusion of the warranty therefore applies exclusively in B2B dealings, which the Store concerns, because the Store does not service consumers.

  5. Preservation of statutory claims. Irrespective of the limitations specified above, the Qualified Buyer is entitled to the compensation claims provided for by the universally binding provisions of Polish law and the law of the European Union, which cannot be excluded or limited by contract.

§ 8. Compliance with Polish law and the law of the European Union

  1. Applicable law. To contracts of sale concluded via the Store, to the operation of the Store, and to the interpretation of all legal documents of the Store (including this Research Disclaimer), Polish law applies, including in particular: 1) the Act of 23 April 1964 — the Polish Civil Code (consolidated text: Journal of Laws of 2025, item 250 [VERIFY — discrepancy with the Product Disclaimer, which indicates Journal of Laws of 2025, item 1610; harmonise the correct publication number], as amended); 2) the Act of 6 June 1997 — the Penal Code (consolidated text: Journal of Laws of 2025, item 17, as amended); 3) the Act of 6 September 2001 — Pharmaceutical Law (consolidated text: Journal of Laws of 2025, item 750, as amended); 4) the Act of 30 May 2014 on Consumer Rights (consolidated text: Journal of Laws of 2024, item 1796, as amended); 5) the Act of 18 July 2002 on Providing Services by Electronic Means (consolidated text: Journal of Laws of 2020, item 344, as amended); 6) the Act of 10 May 2018 on the Protection of Personal Data (Journal of Laws of 2018, item 1000, as amended); 7) the Act of 25 February 2011 on Chemical Substances and Their Mixtures (consolidated text: Journal of Laws of 2025, item 196, as amended); 8) the Act of 11 March 2004 on the Tax on Goods and Services (consolidated text: Journal of Laws of 2025, item 222, as amended); 9) the Act of 15 February 1992 on Corporate Income Tax (consolidated text: Journal of Laws of 2024, item 1325, as amended).

  2. Law of the European Union. The Operator points to the direct application of the provisions of European Union regulations: 1) Regulation (EU) 2016/679 of the European Parliament and of the Council (GDPR / RODO); 2) Regulation (EC) No 1907/2006 of the European Parliament and of the Council (REACH); 3) Regulation (EC) No 1272/2008 of the European Parliament and of the Council (CLP); 4) Regulation (EU) No 528/2012 of the European Parliament and of the Council (biocidal products); 5) Regulation (EU) 2017/745 of the European Parliament and of the Council (medical devices); 6) Regulation (EC) No 1223/2009 of the European Parliament and of the Council (cosmetic products); 7) Regulation (EC) No 178/2002 (general food law); 8) Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers (OJ EU L 304 of 22 November 2011, p. 18, as amended) — to the extent that it applies auxiliarily to the categorisation of goods covered by trade.

  3. Conflict-of-laws rules. 1) The application of the law applicable to contractual obligations takes place on the basis of Regulation (EC) No 593/2008 of the European Parliament and of the Council of 17 June 2008 on the law applicable to contractual obligations (Rome I) — OJ EU L 177 of 4 July 2008, p. 6, as amended. 2) The application of the law applicable to non-contractual obligations takes place on the basis of Regulation (EC) No 864/2007 of the European Parliament and of the Council of 11 July 2007 on the law applicable to non-contractual obligations (Rome II) — OJ EU L 199 of 31 July 2007, p. 40, as amended. 3) The jurisdiction of the courts of the Member States of the European Union is governed by Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters (Brussels I bis) — OJ EU L 351 of 20 December 2012, p. 1, as amended.

  4. Competent court. Disputes arising from contracts of sale concluded via the Store are resolved by the common court having local jurisdiction over the registered office of the Operator (the District Court or the Regional Court in Gdańsk — respectively according to the value of the subject matter of the dispute and the category of the case), subject to the universally binding provisions on judicial jurisdiction. This jurisdictional clause applies in professional B2B commercial dealings; it does not apply to consumers, because the Store does not service consumers.

  5. Geographical restrictions. The Operator does not conduct sales to territories subject to international sanctions (§ 5 para. 2 point 11 of this document). Orders from states subject to a geographical blockade are automatically rejected by the Store’s system.

  6. Compliance standards. The Operator declares the implementation of compliance standards appropriate for trade in chemical substances at laboratory scale, including: 1) REACH standards for trade in chemical substances (§ 11 of this document); 2) CLP standards for classification, labelling and packaging (§ 11 of this document); 3) GDPR (RODO) standards for the processing of the personal data of Qualified Buyers (regulated separately in the Store’s Privacy Policy); 4) AML standards — in a proactive dimension, even though the Operator is not an obliged institution within the meaning of Art. 2 para. 1 of the Act of 1 March 2018 on Counteracting Money Laundering and the Financing of Terrorism (consolidated text: Journal of Laws of 2023, item 1124, as amended). The Operator introduces internal alert thresholds for single orders: EUR 5,000, EUR 15,000, EUR 50,000 — exceeding a threshold results in the activation of an additional procedure for verifying the Qualified Buyer and possible notification of the General Inspector of Financial Information (GIIF) in situations justified by suspicion.

  7. No obligation to appoint a Data Protection Officer (DPO). The Operator carried out an analysis of the obligations arising from Art. 37 para. 1 GDPR (RODO) and found that the conditions for the mandatory appointment of a Data Protection Officer (DPO) do not arise, because: 1) the Operator is not a public authority or body (Art. 37 para. 1 let. a GDPR (RODO)); 2) the core activity of the Operator does not consist of processing operations requiring regular and systematic monitoring of data subjects on a large scale (Art. 37 para. 1 let. b GDPR (RODO)); 3) the core activity of the Operator does not consist of the large-scale processing of special categories of personal data or data relating to criminal convictions (Art. 37 para. 1 let. c GDPR (RODO)). The contact point in matters of personal data protection remains the address compliance@purepoint.pl.

§ 9. Exclusion of the consumer regime

  1. Primary argument — lack of consumer status on the part of the Qualified Buyer.

1) The Store is conducted exclusively for Qualified Buyers (§ 4 of this Disclaimer). A Qualified Buyer is by definition an entity conducting business, professional, research or academic activity (Art. 43(1) KC). A Qualified Buyer is not a consumer within the meaning of Art. 22(1) KC.

2) Full wording of Art. 22(1) KC: “A consumer shall be deemed to be a natural person performing with an entrepreneur a legal act not directly connected with their business or professional activity.”

3) Full wording of Art. 43(1) KC: “An entrepreneur is a natural person, a legal person and an organisational unit referred to in Art. 33(1) § 1, conducting business or professional activity in their own name.”

4) Since the Qualified Buyer conducts business, professional, research or academic activity and acquires the Products for a purpose connected with that activity, they are not a consumer. The consequence is the non-application of: a) the Act of 30 May 2014 on Consumer Rights (UPK) — in particular Art. 27–39 UPK governing the right to withdraw from a contract concluded at a distance within 14 days; b) the Act of 23 April 1964 — the Polish Civil Code — as regards the provisions protecting the consumer (abusive clauses — Art. 385(1)–385(3) KC, consumer protection in contracts concluded at a distance); c) Directive 2011/83/EU of the European Parliament and of the Council of 25 October 2011 on consumer rights (OJ EU L 304 of 22 November 2011, p. 64, as amended); d) Directive (EU) 2019/2161 of the European Parliament and of the Council of 27 November 2019 (Omnibus) — as regards information obligations towards consumers.

5) The Qualified Buyer is aware that, by accepting the KOP (§ 4 para. 6) and by concluding a contract of sale within the Store, they expressly declare a lack of consumer status, which means the non-application of the consumer protection provisions indicated above.

  1. Fallback argument — exclusions under Art. 38 UPK.

Irrespective of the primary argument (lack of consumer status), the Operator indicates that even in a hypothetical situation in which one of the Qualified Buyers were to be deemed to have consumer status, the right to withdraw from a contract concluded at a distance would be excluded on the basis of Art. 38 of the Act of 30 May 2014 on Consumer Rights. The following exclusionary conditions in particular are invoked:

1) Art. 38 point 3 UPK — the exclusion of contracts in which the subject matter of the performance is a non-prefabricated item produced according to the consumer’s specification or serving to satisfy their individualised needs. The Products offered in the Store are distributed in analytical packaging containing a specified mass of lyophilisate, with a dedicated batch number (LOT) and with COA analytical documentation assigned to a specific unit of the Product. The choice of a specific nominal mass (e.g. a 5 mg vial vs. a 10 mg vial vs. a 20 mg vial of a given substance) and the choice of a specific production batch (LOT) with a specific chemical purity profile constitute a configuration satisfying the individualised needs of the Qualified Buyer.

2) Art. 38 point 4 UPK — the exclusion of contracts in which the subject matter of the performance is an item liable to deteriorate rapidly or having a short use-by date. The Products offered in the Store are peptide substances in the form of a lyophilisate with a relatively short expiration date (typically 24 months from the date of manufacture in the state of lyophilisate sealed in a vial; after reconstitution in a solvent — significantly shorter, under refrigerated storage conditions). The Products require specific storage conditions (refrigerated, at a temperature of 2–8 °C for some substances, under deep-freeze conditions for others), and any deviation from the storage conditions during return transport (e.g. a return after 14 days with storage at room temperature) results in the loss of the analytical quality of the Product and a breach of the COA designation, which means that the Product after return is not fit for further trade.

3) Art. 38 point 5 UPK — the exclusion of contracts in which the subject matter of the performance is an item delivered in a sealed package, which after the opening of the package cannot be returned for reasons of health protection or for hygienic reasons, if the package was opened after delivery. The Products are delivered in vials with a hermetic aluminium or rubber closure, with a tamper-evident seal. Any breach of the seal means the opening of the package, and in trade in chemical substances intended for analytical work an opened package loses its analytical value (exposure to air, moisture, light may affect the physicochemical properties of the substance). From the perspective of health protection (counteracting the unlawful introduction of the Product into consumer trade as a result of a return and resale), the return of an opened package is excluded absolutely.

4) The combined application of the exclusions under Art. 38 points 3, 4 and 5 UPK reinforces the argumentation excluding the right to withdraw from the contract in relation to the Products offered in the Store.

  1. Legal conclusion. 1) The primary argument (lack of consumer status) excludes the application of the consumer regime in its entirety. 2) The fallback argument (Art. 38 UPK) excludes the right to withdraw from the contract even in the hypothetical situation of a Qualified Buyer being deemed a consumer. 3) Consequently, the Qualified Buyer does not have the right to withdraw from a contract concluded at a distance within 14 days in relation to the Products acquired in the Store.

  2. Complaints regarding physical defects and non-conformity with the description. Despite the exclusion of the consumer regime and the exclusion of the B2B warranty (Art. 558 § 1 KC in conjunction with § 7 para. 9 of this document), the Operator applies voluntary complaint procedures described in the Complaints and Returns Policy available on the Store’s website. These procedures cover in particular situations of: 1) non-conformity of the received Product with the description set out in the Product card (e.g. a different substance than ordered, a different nominal mass than ordered); 2) a visible physical defect of the packaging preventing the safe use of the Product (e.g. a cracked vial with a visible leak); 3) the absence of COA documentation assigned to the specific batch.

  3. Information clause. Before concluding the contract, the Qualified Buyer is informed in a clear and legible manner of the absence of the right to withdraw from a contract concluded at a distance. This information is placed: 1) in the content of this Research Disclaimer (§ 9 para. 3 point 3); 2) in the Store Terms; 3) directly in the content of the basket and the order summary screen.

§ 10. Product batch documentation — COA, LOT, MFG, EXP

  1. Documentation requirement. Each batch of the Product placed on the market by the Operator is covered by analytical documentation comprising: 1) a Certificate of Analysis (COA) — a document issued by the manufacturer or an independent analytical laboratory, confirming the chemical identity and analytical parameters of a given batch of the Product; 2) a batch number (LOT) — a designation enabling the unambiguous identification of the production batch; 3) a manufacturing date (MFG) — the date of completion of the production process of a given batch (the date of release to the market after the completion of quality control); 4) an expiration date (EXP) — the date up to which the analytical properties of the Product are guaranteed, provided that the recommended storage conditions are maintained.

  2. Content of the Certificate of Analysis (COA). The COA document issued for a given batch of the Product contains in particular: 1) the chemical name of the active substance (the customary chemical name and — as far as available — the amino acid sequence for peptide substances); 2) the CAS number (Chemical Abstracts Service), provided that the substance has an assigned CAS number; 3) the molecular formula and the calculated molecular weight; 4) the result of the purity analysis by reversed-phase high-performance liquid chromatography with a gradient (RP-HPLC), expressed as a percentage of the area of the main peak (purity of typically ≥ 98.0% being required); 5) the result of the identity analysis by mass spectrometry (MS, most often ESI-MS) with a comparison of the measured molecular weight with the calculated one; 6) the content of trifluoroacetate (TFA) from the purification procedure, if applicable; 7) the water content (usually by the Karl Fischer method or TGA); 8) the external appearance (typically “white to off-white lyophilized powder”); 9) the batch number (LOT) and the manufacturing date (MFG); 10) the date of issue of the COA and the signature of the person responsible for issuing the document.

  3. Procedure for issuing the COA to the Qualified Buyer. 1) The COA document for each batch of the Product is made available to the Qualified Buyer in the Store’s order management panel free of charge. 2) As standard, the COA is available for download from the Qualified Buyer’s panel in the form of a PDF file no later than at the moment of shipment of the Product. 3) Upon a written request addressed to compliance@purepoint.pl, the Operator issues an additional copy of the COA bearing an electronic signature or company stamp within 7 business days from the date of receipt of the request. 4) The COA document is associated with a specific batch number (LOT) — with each delivery the Operator ensures consistency: the LOT number appearing on the vial label must match the LOT number appearing on the COA.

  4. Storage of batch documentation by the Operator. 1) The Operator stores the full documentation of each batch of the Product placed on the market for a period of at least 5 years from the date of exhaustion of the given batch, irrespective of the expiration date (EXP). 2) The batch documentation comprises: the COA, delivery documents from the manufacturer or an intermediary distributor, import documents (if the batch was imported from outside the EU), purchase invoices, warehouse documentation (storage conditions), technical correspondence with the manufacturer concerning the batch. 3) The Operator makes this documentation available to public administration authorities and law enforcement authorities on request, to the extent arising from the provisions of the law (§ 13 of this document).

  5. Batch withdrawal procedure. 1) In the event of the disclosure on the part of the manufacturer or the Operator of information about an analytical defect of a given batch (e.g. non-conformity of the actual parameters with those declared in the COA, detection of undeclared contaminants, an error in the identification of the active substance), the Operator immediately withholds the sale of all units of that batch located in the Operator’s warehouse. 2) The Operator notifies all Qualified Buyers who received Products from the defective batch within 7 business days from the date of obtaining reliable knowledge of the defect. 3) The Operator offers the exchange of the batch for a correct batch or a refund of the purchase price (at the choice of the Qualified Buyer). 4) The Operator retains the full documentation of the withdrawal incident (Recall Documentation) for compliance purposes and any control proceedings.

  6. Storage conditions of the Products. 1) The Operator recommends storing the Products under the conditions indicated on the label and in the safety data sheet (SDS) — usually under refrigerated conditions (2–8 °C) or in deep-freeze (-20 °C or lower) for particularly sensitive substances. 2) After reconstitution in a solvent, the shelf life is significantly shorter and is each time determined on the basis of an individual assessment of the stability of the solution — information provided in the COA or in the description of the Product. 3) The Qualified Buyer bears full liability for ensuring the appropriate storage conditions of the Product from the moment of receipt from the courier.

  7. No guarantee of pharmacological properties. The COA document confirms exclusively the analytical parameters of the Product (identity, purity, HPLC result, MS result, TFA content, water content). The COA document does not confirm and is not evidence of any pharmacological, therapeutic, cosmetic, supplement, biocidal or other functional properties of the Product. There are no declarations whatsoever concerning efficacy, safety, or effect on the organism of a human or animal. Any attempts to interpret the COA as a document confirming the permissibility of using the Product for therapeutic or supplement purposes are groundless and contrary to § 3 of this document.

§ 11. CLP-compliant labelling and REACH-compliant safety data sheets (SDS)

  1. Labelling of the Products in accordance with CLP (Regulation (EC) No 1272/2008).

1) The Operator ensures that the Products offered in the Store are labelled in accordance with the requirements of Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures (CLP).

2) The label of each vial of the Product contains at least: a) the chemical name of the substance (the customary chemical name and — as far as available — the amino acid sequence for peptide substances); b) the CAS number, provided that the substance has an assigned CAS number; c) the batch number (LOT) and the manufacturing date (MFG); d) the net mass of the substance in the vial (e.g. “5 mg”, “10 mg”); e) the safety inscription “FOR RESEARCH USE ONLY — NOT FOR HUMAN OR ANIMAL CONSUMPTION” clearly highlighted; f) the Operator’s data (name, KRS, address of the registered office); g) if the substance is classified as hazardous in accordance with CLP — the appropriate hazard pictograms, signal word (Danger / Warning), hazard statements (H-statements) and precautionary statements (P-statements); h) the recommended storage conditions (temperature, humidity).

3) If a peptide substance is not subject to mandatory classification as hazardous in accordance with CLP (the predominant case for typical research peptides), the Operator places on the label the technical information “Substance not classified as hazardous in accordance with Regulation (EC) No 1272/2008 (CLP). Substance intended exclusively for in vitro laboratory work.”

  1. Safety data sheets (SDS) compliant with REACH (Art. 31 of Regulation (EC) No 1907/2006).

1) The Operator ensures access to safety data sheets for chemical substances (Safety Data Sheets, SDS) for the Products offered in the Store, in accordance with Art. 31 of Regulation (EC) No 1907/2006 (REACH).

2) The SDS safety data sheet is drawn up in the Polish language (in accordance with Art. 31 para. 5 REACH) and additionally in the English language for the purposes of cross-border trade within the EEA.

3) The SDS safety data sheet contains 16 sections in accordance with Annex II to the REACH Regulation, in particular: a) section 1 — identification of the substance and identification of the supplier; b) section 2 — hazards identification; c) section 3 — composition / information on ingredients; d) section 4 — first aid measures; e) section 5 — firefighting measures; f) section 6 — accidental release measures; g) section 7 — handling and storage; h) section 8 — exposure controls / personal protection; i) section 9 — physical and chemical properties; j) section 10 — stability and reactivity; k) section 11 — toxicological information; l) section 12 — ecological information; m) section 13 — disposal considerations; n) section 14 — transport information; o) section 15 — regulatory information; p) section 16 — other information.

4) SDS provision procedure. The SDS safety data sheets are available for download from the Qualified Buyer’s panel in the form of a PDF file no later than at the moment of delivery of the Product. Upon a written request addressed to compliance@purepoint.pl, the Operator issues an additional copy of the SDS within 7 business days from the date of receipt of the request.

5) In the event of a material update of the SDS safety data sheet (a change in classification, new toxicological information, a change in safety recommendations), the Operator notifies all Qualified Buyers who acquired the given substance within the last 12 months of the update and makes the updated version of the SDS available (Art. 31 para. 9 REACH).

  1. Packaging compliant with REACH and CLP. 1) The Products are packaged in analytical packaging — type I or type II glass vials in accordance with the pharmacopoeial classification (or equivalent per ASTM/ISO) with a capacity of 2–3 ml, with a hermetic aluminium or rubber closure dedicated to laboratory conditions, with a tamper-evident seal. 2) The bulk packaging for shipment meets the standards for the transport of chemical substances at analytical scale, with the maintenance of refrigerated conditions where necessary (cool packs, insulated thermoboxes).

  2. REACH compliance — registration status. 1) The Operator is not a manufacturer or importer of peptide substances within the meaning of the REACH Regulation in respect of the majority of the offered Products; it performs the function of a retail distributor in domestic or intra-EU trade of substances acquired from manufacturers and wholesale distributors meeting the requirements of REACH. 2) The peptide substances offered in the Store are placed on the EU market in quantities below the thresholds of mandatory REACH registration (below 1 tonne per year per manufacturer/importer for a given substance), which constitutes an exemption from the obligation of proper registration in accordance with Art. 6 of the REACH Regulation. 3) Alternatively, some of the peptide substances may be covered by the PPORD exemption (Product and Process Oriented Research and Development) in accordance with Art. 9 of the REACH Regulation, as substances used exclusively for scientific research and development. 4) The Operator retains documentation confirming the REACH registration status of each substance offered in the Store.

  3. Information on REACH restrictions. The Operator monitors Annexes XIV (the List of substances subject to authorisation) and XVII (Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles) to the REACH Regulation. In the event of the inclusion of a peptide substance in one of these annexes, the Operator adjusts the trade in accordance with the requirements (obtaining authorisation, withholding sale, restricting the scope of applications).

§ 12. Procedure for introducing amendments to this Research Disclaimer

  1. Principle of the right to amend. The Operator reserves the right to make amendments to the content of this Research Disclaimer for important reasons, in particular: 1) in the event of a change in the universally binding provisions of Polish law or the law of the European Union affecting the content of the Disclaimer; 2) in the event of a change in the practice of public administration authorities, in particular the GIF, URPL, GIS, UODO, UOKiK; 3) in the event of the issuance of a final court judgment or administrative decision affecting the interpretation of the provisions of the Disclaimer; 4) in the event of a change in the Store’s product range, in particular the introduction into the offer of new categories of substances requiring a supplement to the content of the document; 5) in the event of a change in the data identifying the Operator (company name, address of the registered office, KRS, NIP, REGON, representation); 6) in the event of a change in service providers (payment operator, hosting, analytics, newsletter); 7) in the event of the detection of editorial errors, internal inconsistencies, ambiguities requiring clarification; 8) in the event of the implementation of recommendations arising from compliance audits conducted by the Operator.

  2. Exclusion of worsening the situation of the Qualified Buyer. An amendment to the content of the Research Disclaimer may not worsen the legal situation of the Qualified Buyer in respect of orders placed and paid for before the date of entry into force of the amendment. For such orders, the content of the Research Disclaimer in the version current on the date of placing the order applies.

  3. Procedure for introducing amendments. 1) The draft amendment is prepared by an authorised compliance employee or a legal adviser of the Operator. 2) The draft is reviewed by the Member of the Management Board (Krystian Dawidowski) from a managerial and operational perspective. 3) Once accepted, the draft is published in a new version of the document (with an increment of the version number — e.g. from 2.0 to 2.1, or from 2.1 to 3.0 in the event of a structural change) on the Store’s website at https://purepoint.pl/zastrzezenie-badawcze/ with the indication of the date of entry into force of the new version. 4) All Qualified Buyers holding an active account in the Store are informed of the amendment by electronic means (to the e-mail address assigned to the account) with at least 14 days’ notice before the date of entry into force of the new version. 5) Use of the Store after the date of entry into force of the new version of the Disclaimer constitutes acceptance of its content.

  4. Versioning. Each version of the Research Disclaimer is marked with a number (X.Y), a date of entry into force and an annotation on the scope of the changes (the “Change history” section at the end of the document). The Operator retains a full archive of earlier versions of the document — earlier versions are available upon a request addressed to compliance@purepoint.pl.

  5. Urgent amendments arising from the legal situation. In the event of a change in the universally binding provisions of the law requiring immediate adjustment of the document (e.g. the entry into force of an amendment to the Pharmaceutical Law), the Operator has the right to shorten the notification period to 3 business days, while retaining the obligation to inform the Qualified Buyers by electronic means.

  6. Withholding of actions requiring the KOP after an amendment. In the period between the notification and the entry into force of the new version of the KOP, the need may arise for the Qualified Buyers to re-make the KOP declarations, if the amendment concerns the content of those declarations. In such a case, the Operator informs the Qualified Buyers of the re-declaration procedure in the Qualified Buyer’s panel.

§ 13. Clause on cooperation with public administration authorities and law enforcement authorities

  1. Full cooperation of the Operator. The Operator declares full and unconditional cooperation with all public administration authorities and law enforcement authorities entitled to conduct control, explanatory, investigative or administrative proceedings in matters connected with the operation of the Store, the legal nature of the Products, the manner of trade in them, and the personal data of the Qualified Buyers.

  2. List of authorities covered by the cooperation clause. The Operator cooperates in particular with:

1) the Chief Pharmaceutical Inspector (GIF) with its registered office in Warsaw and voivodeship pharmaceutical inspectors, as regards control activities conducted on the basis of the Act of 6 September 2001 — Pharmaceutical Law, in particular on the basis of Art. 108–122 PF (control of trade in medicinal products). The Operator makes available batch documentation, supplier documentation, warehouse documentation and other documents necessary to conduct the control activities within the time limits and under the procedure specified by the authority;

2) the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) with its registered office in Warsaw, as regards activities conducted on the basis of the Act of 18 March 2011 on the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (consolidated text: Journal of Laws of 2023, item 1098, as amended) and specific statutes governing trade in medicinal products, medical devices and biocidal products;

3) the Chief Sanitary Inspector (GIS) and the State Sanitary Inspection (voivodeship and district authorities), as regards activities conducted on the basis of the Act of 14 March 1985 on the State Sanitary Inspection (consolidated text: Journal of Laws of 2024, item 1090, as amended), the Act of 25 August 2006 on Food and Nutrition Safety, and the Act of 4 October 2018 on Cosmetic Products;

4) the President of the Personal Data Protection Office (UODO) with its registered office in Warsaw, as regards activities conducted on the basis of the Act of 10 May 2018 on the Protection of Personal Data and the GDPR (RODO). The Operator ensures access to the personal data processing documentation, including the record of processing activities (RoPA), internal policies and procedures, and data protection audit reports;

5) the President of the Office of Competition and Consumer Protection (UOKiK) with its registered office in Warsaw, as regards activities conducted on the basis of the Act of 16 February 2007 on Competition and Consumer Protection (consolidated text: Journal of Laws of 2024, item 594, as amended) — with the reservation that the Operator takes the position that the Store does not service consumers (§ 9 of this document), and accordingly the jurisdiction of the UOKiK in matters of consumer protection has a significantly limited application to the Store;

6) the authorities of the National Revenue Administration, including customs authorities, as regards trade in chemical substances across the EU customs border (import and export), ensuring compliance with customs and tax provisions, TARIC documentation, customs declarations;

7) the Police and the prosecutor’s office (law enforcement authorities), as regards notifications of a reasonable suspicion of the commission of a crime, in particular in the event of: a) the making by the Qualified Buyer of a false KOP declaration (Art. 233 KK — § 6 of this document); b) use of the Product for the purpose of committing a prohibited act (§ 5 para. 2 point 12 of this document); c) impersonating the Operator in trade in counterfeit Products; d) attempts at fraud or unfair competition; e) cybercrime directed against the Store or the Qualified Buyers;

8) the General Inspector of Financial Information (GIIF), as regards proactive notifications in the event of the occurrence of suspicions connected with counteracting money laundering and the financing of terrorism, even though the Operator is not an obliged institution within the meaning of Art. 2 para. 1 of the Act of 1 March 2018 on Counteracting Money Laundering and the Financing of Terrorism — § 8 para. 6 point 4 of this document;

9) the European Chemicals Agency (ECHA) with its registered office in Helsinki (Finland) — as regards the exchange of information concerning chemical substances covered by the REACH Regulation (PPORD registration, notifications in the SCIP database), in the event of a request being addressed by ECHA;

10) other public administration authorities of the Republic of Poland and authorities of the European Union, as regards their statutory competences relating to the Operator’s activity.

  1. Manner and form of cooperation. 1) The Operator designates as the contact point for public administration authorities and law enforcement authorities the e-mail address compliance@purepoint.pl and the electronic delivery address (ADE / e-Delivery): AE:PL-21312-60691-FGBFV-19. 2) The Operator provides responses to the requests of the authorities within the time limits specified by those authorities (customarily within 7 business days for written requests, within 24 hours for urgent requests in criminal proceedings). 3) In the event of the need to make the personal data of the Qualified Buyers available to public administration authorities and law enforcement authorities, the Operator carries out an analysis of the legal basis of the request and — if the request is lawful — makes the data available under the procedure and to the extent specified by the provisions of the General Data Protection Regulation (GDPR / RODO), in particular Art. 6 para. 1 let. c, e and f GDPR (RODO). 4) In the event of a request being made that is unlawful, the Operator refuses to make the data available and notifies the authority of the reasons for the refusal.

  2. Transparency towards the Qualified Buyers. The Operator publishes on the Store’s website an annual transparency report containing aggregated information on the number and nature of requests addressed by public administration authorities and law enforcement authorities, while maintaining the principles of confidentiality of proceedings and the protection of the personal data of third parties. The report is published no later than 30 June of the year following the year to which it relates.

  3. Maintaining the confidentiality of proceedings. The Operator undertakes to maintain confidentiality as to the control and criminal proceedings conducted, to the extent and under the procedure required by the provisions on the protection of the secrecy of proceedings. In particular, the Operator does not inform the Qualified Buyers of ongoing proceedings in which the maintenance of secrecy is required by law.

§ 14. Bibliography — acts of Polish and EU law on which the document is based

The list below contains the legal acts on which the content of this Research Disclaimer is based. The list is not exhaustive and does not exclude the application of other universally binding provisions of Polish law and the law of the European Union.

A. Acts of Polish law (of statutory rank).

  1. The Act of 23 April 1964 — the Polish Civil Code (consolidated text: Journal of Laws of 2025, item 250 [VERIFY — discrepancy with the Product Disclaimer, which indicates Journal of Laws of 2025, item 1610; harmonise the correct publication number], as amended).
  2. The Act of 6 June 1997 — the Penal Code (consolidated text: Journal of Laws of 2025, item 17, as amended).
  3. The Act of 6 June 1997 — the Code of Criminal Procedure (consolidated text: Journal of Laws of 2025, item 18, as amended).
  4. The Act of 6 September 2001 — Pharmaceutical Law (consolidated text: Journal of Laws of 2025, item 750, as amended; earlier consolidated text: Journal of Laws of 2024, item 686, as amended), with reference to Art. 2 point 32 (definition of a medicinal product) and Art. 124 para. 1 (the sanction for placing a medicinal product on the market without authorisation — a fine, the penalty of restriction of liberty or imprisonment of up to 2 years).
  5. The Act of 30 May 2014 on Consumer Rights (consolidated text: Journal of Laws of 2024, item 1796, as amended), in particular Art. 27–39.
  6. The Act of 18 July 2002 on Providing Services by Electronic Means (consolidated text: Journal of Laws of 2020, item 344, as amended).
  7. The Act of 10 May 2018 on the Protection of Personal Data (Journal of Laws of 2018, item 1000, as amended).
  8. The Act of 25 February 2011 on Chemical Substances and Their Mixtures (consolidated text: Journal of Laws of 2025, item 196, as amended).
  9. The Act of 25 August 2006 on Food and Nutrition Safety (consolidated text: Journal of Laws of 2023, item 1448, as amended).
  10. The Act of 4 October 2018 on Cosmetic Products (Journal of Laws of 2018, item 2227, as amended).
  11. The Act of 7 April 2022 on Medical Devices (Journal of Laws of 2022, item 974, as amended).
  12. The Act of 9 October 2015 on Biocidal Products (consolidated text: Journal of Laws of 2024, item 211, as amended).
  13. The Act of 1 March 2018 on Counteracting Money Laundering and the Financing of Terrorism (consolidated text: Journal of Laws of 2023, item 1124, as amended).
  14. The Act of 14 March 1985 on the State Sanitary Inspection (consolidated text: Journal of Laws of 2024, item 1090, as amended).
  15. The Act of 16 February 2007 on Competition and Consumer Protection (consolidated text: Journal of Laws of 2024, item 594, as amended).
  16. The Act of 15 January 2015 on the Protection of Animals Used for Scientific or Educational Purposes (Journal of Laws of 2023, item 465, as amended).
  17. The Act of 18 March 2011 on the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (consolidated text: Journal of Laws of 2023, item 1098, as amended).
  18. The Act of 20 July 2000 on the Promulgation of Normative Acts and Certain Other Legal Acts (consolidated text: Journal of Laws of 2019, item 1461, as amended).

B. Acts of European Union law.

  1. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation — GDPR / RODO) (OJ EU L 119 of 4 May 2016, p. 1, as amended).
  2. Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (OJ EU L 396 of 30 December 2006, p. 1, as amended), in particular Art. 6, 9 and 31.
  3. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures (CLP) (OJ EU L 353 of 31 December 2008, p. 1, as amended).
  4. Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ EU L 167 of 27 June 2012, p. 1, as amended).
  5. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (OJ EU L 117 of 5 May 2017, p. 1, as amended).
  6. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (OJ EU L 342 of 22 December 2009, p. 59, as amended).
  7. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law (OJ EU L 31 of 1 February 2002, p. 1, as amended).
  8. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ EU L 311 of 28 November 2001, p. 67, as amended).
  9. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ EU L 183 of 12 July 2002, p. 51, as amended).
  10. Directive 2011/83/EU of the European Parliament and of the Council of 25 October 2011 on consumer rights (OJ EU L 304 of 22 November 2011, p. 64, as amended).
  11. Directive (EU) 2019/2161 of the European Parliament and of the Council of 27 November 2019 — “Omnibus” (OJ EU L 328 of 18 December 2019, p. 7).
  12. Regulation (EC) No 593/2008 of the European Parliament and of the Council of 17 June 2008 on the law applicable to contractual obligations (Rome I) (OJ EU L 177 of 4 July 2008, p. 6, as amended).
  13. Regulation (EC) No 864/2007 of the European Parliament and of the Council of 11 July 2007 on the law applicable to non-contractual obligations (Rome II) (OJ EU L 199 of 31 July 2007, p. 40, as amended).
  14. Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters (Brussels I bis) (OJ EU L 351 of 20 December 2012, p. 1, as amended).
  15. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers (OJ EU L 304 of 22 November 2011, p. 18, as amended).

Change history

Version Effective date Scope of changes
1.0 2026-05-22 (revision: 2026-05-24) First version of the Research Disclaimer — introduction of the main clauses (research-use-only, B2B, no consumer rights). Internal compliance review.
2.0 2026-06-06 Full restructuring of the document. Introduction of the “top of stack” hierarchy in relation to the remaining legal documents of the Store. Introduction of a full negative regulatory classification for all categories (medicinal products, dietary supplements, cosmetics, medical devices, foodstuffs, biocidal products) with a functional justification for each exclusion. Introduction of the five categories of Qualified Buyer (STUDENT / LAB / SCIENTIST / BIZ_RD / OTHER_PRO) and the Qualified Profile Declaration (KOP). Introduction of the list of 14 absolutely prohibited types of conduct. Corrigendum to Art. 124 PF (penalty of imprisonment of up to 2 years, and not 8 years / PLN 5 million). Introduction of the B2B liability cap, the exclusion of lucrum cessans, the exclusion of the B2B warranty (Art. 558 § 1 KC). Introduction of the double argument for the exclusion of the consumer regime (Art. 22(1) + 43(1) KC and Art. 38 points 3, 4, 5 UPK). Introduction of the batch documentation procedure (COA, LOT, MFG, EXP). Introduction of the CLP labelling and REACH SDS rules. Introduction of the clause on cooperation with public administration authorities and law enforcement authorities. Full bibliography of 33 PL/EU acts.

Final clause

In the matters not regulated by this document, the universally binding provisions of Polish law and the law of the European Union apply. In the event of interpretative doubts, please contact compliance@purepoint.pl.

Version: 2.0 Effective date: 6 June 2026 Operator: FIRSTSTONE TRADING sp. z o.o. Representation: Krystian Dawidowski — Member of the Management Board Compliance contact point: compliance@purepoint.pl ADE / e-Delivery: AE:PL-21312-60691-FGBFV-19

Other Legal Center documents

  • Product Disclaimer
  • Acceptable Use Policy
  • Store Terms & Conditions
  • Shipping Policy
  • Returns Policy
  • Complaints Policy
  • Consumer Clauses B2C vs B2B
  • Privacy Policy
  • Cookies Policy
  • User Account Terms
  • Newsletter Terms
  • Compliance Notice
  • AML/KYC Policy
  • Sanctions & Export Policy
  • Impressum / Operator Details

Back to the Legal Center — full list of 15 documents

Research newsletter
New write-ups and documentation — straight to your inbox.
SOLKUR.COM

Laboratory-grade research materials. Verified purity. Batch documentation on every SKU.

Navigation
  • Shop
  • Quality
  • FAQ
  • About
  • Contact
Legal Center

Positioning

  • Research Disclaimer
  • Product Disclaimer
  • AUP

Sales

  • Terms & Conditions
  • Shipping Policy
  • Returns Policy
  • Complaints Policy
  • B2C/B2B Clauses

Privacy

  • Privacy Policy
  • Cookies Policy
  • Account Terms
  • Newsletter Terms

Compliance

  • Compliance Notice
  • Safety Data Sheets (SDS)
  • AML/KYC Policy
  • Sanctions Policy
  • Impressum
Contact
  • info@solkur.com
  • compliance@solkur.com
  • @solkur.com

Legal disclaimer. All products offered by PUREPOINT Supply are intended for research and laboratory purposes only. They are not intended for human or animal consumption, are not medicinal products, dietary supplements or cosmetics, and must not be used for diagnostic or therapeutic purposes.

Operator: FIRSTSTONE TRADING sp. z o.o. · KRS 0001254766 · NIP 7831958614

© 2026 FIRSTSTONE TRADING sp. z o.o. All rights reserved.

Search products

⌘K

Enter at least 2 characters to see results.

Popular

Searching…

No results for your query.

Try entering a peptide name (e.g. „BPC-157”) or a category (e.g. „regeneration”).

    Full product catalogue → Research materials — for laboratory use only.
    ✓
    Added to cart

    Frequently studied together

    Go to cart →
    Research guide Build the peptide stack your research calls for Pick your direction — we curate the set and explain every choice. Build my stack
    Build my stack
    PurePoint is a brand of FIRSTSTONE TRADING sp. z o.o. — a registered Polish company. KRS 0001254766 · NIP PL7831958614 · Verify us in the KRS register ↗
    Shipped from Poland · VAT invoice · COA for every batch · contact: contact@purepoint.pl
    Materials for research purposes only. Not for human or animal consumption.